Bernier Virginie, Lagacé Monique, Bichet Daniel G, Bouvier Michel
Département de Biochimie and Le Groupe de Recherche sur le Système Nerveux Autonome, Université de Montréal, H3T 1J4, Canada.
Trends Endocrinol Metab. 2004 Jul;15(5):222-8. doi: 10.1016/j.tem.2004.05.003.
Increasing numbers of inherited diseases are found to result from mutations that lead to misfolded proteins. In many cases, the changes in conformation are relatively modest and the function of the protein would not be predicted to be affected. Yet, these proteins are recognized as "misfolded" and degraded prematurely. Recently, small molecules known as chemical and pharmacological chaperones were found to stabilize such mutant proteins and facilitate their trafficking to their site of action. Here, we review the recent published evidence suggesting that pharmacological chaperones represent promising avenues for the treatment of endocrine and metabolic diseases such as hyperinsulinemic hypoglycemia, hypogonadotropic hypogonadism and nephrogenic diabetes insipidus, and might become a general therapeutic strategy for the treatment of conformational diseases.
越来越多的遗传性疾病被发现是由导致蛋白质错误折叠的突变引起的。在许多情况下,构象变化相对较小,预计蛋白质的功能不会受到影响。然而,这些蛋白质被识别为“错误折叠”并过早降解。最近,被称为化学和药理伴侣分子的小分子被发现可以稳定此类突变蛋白,并促进它们运输到作用位点。在这里,我们综述了最近发表的证据,表明药理伴侣分子为治疗内分泌和代谢疾病(如高胰岛素血症性低血糖症、低促性腺激素性性腺功能减退和肾性尿崩症)提供了有前景的途径,并且可能成为治疗构象疾病的一种通用治疗策略。